Core Viewpoint - Metallus Inc. is under investigation for potential securities fraud and unlawful business practices following disappointing financial results for Q1 2025, which led to a significant drop in stock price [1][3]. Financial Performance - Metallus reported non-GAAP earnings per share of $0.07 for Q1 2025, missing consensus estimates by $0.05 [3]. - The company's stock price fell by $1.48, or 11.31%, closing at $11.61 per share on May 9, 2025, following the earnings announcement [3]. Company Challenges - The CEO of Metallus indicated that the company experienced volatility in the defense supply chain during Q1 2025, attributed to customer manufacturing start-up challenges [3].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Redwire Corporation and its executives, following disappointing financial results and stock price decline [1][3]. Financial Performance - Redwire reported Q1 2025 revenue of $61.4 million, which was $13.14 million below consensus estimates, marking a 30.1% decline year-over-year [3]. - The company attributed the revenue shortfall to delays in U.S. government contract awards, linked to leadership transitions at agencies such as NASA and the Space Development Agency, as well as changing budget priorities under the Trump administration [3]. Stock Market Reaction - Following the release of the financial results, Redwire's stock price decreased by $0.75, or 6.63%, closing at $10.56 per share on May 12, 2025 [4].

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Travere Therapeutics, Inc. and its officers or directors [1] Group 1: Company Developments - On May 15, 2025, Travere announced that the FDA plans to hold an advisory committee meeting regarding its supplemental New Drug Application for FILSPARI, aimed at treating focal segmental glomerulosclerosis [3] - Following this announcement, Travere's stock price dropped by $4.35, or 20.57%, closing at $16.80 per share on May 16, 2025 [3] Group 2: Legal Investigation - Pomerantz LLP is reaching out to investors of Travere for claims related to potential securities fraud [1] - The firm is recognized for its expertise in corporate, securities, and antitrust class litigation, having a long history of fighting for victims of securities fraud [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud and unlawful business practices involving Fulgent Genetics, Inc. and its officers or directors [1] Group 1: Investigation Details - The investigation is prompted by claims from investors of Fulgent Genetics, Inc. [1] - Investors are encouraged to contact Pomerantz LLP for more information regarding the investigation [1] Group 2: Recent Developments - On February 28, 2025, Fulgent disclosed receiving a civil investigative demand from the U.S. Department of Justice concerning potential false claims under the Uninsured Program [3] - Following this disclosure, Fulgent's stock price decreased by $0.41 per share, or 2.61%, closing at $15.28 per share on March 3, 2025 [3] Group 3: Firm Background - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of over 85 years in the field [4] - The firm has successfully recovered numerous multimillion-dollar damages awards for victims of securities fraud and corporate misconduct [4]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  UroGen Pharma Ltd. (“UroGen” or the “Company”) (NASDAQ: URGN).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether UroGen and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On May 16, 202 ...

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Apple Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Apple announced an indefinite delay in updates to its Siri digital assistant, impacting investor sentiment and leading to a significant drop in stock price [3] - Morgan Stanley analyst Erik Woodring lowered Apple's price target due to the delay in Siri features, which could affect iPhone upgrade cycles [4] Company Developments - Apple has postponed the release of certain Siri features that were initially expected in June 2024, now anticipated to be released in the coming year [3] - Following the announcement of the delay, Apple's stock price fell by $11.59, or 4.85%, closing at $227.48 on March 10, 2025 [3] - The stock price further declined by $11.16, or 5.05%, to close at $209.68 on March 13, 2025, after Morgan Stanley's report [5] Analyst Insights - Morgan Stanley's report indicated that approximately 50% of iPhone owners who did not upgrade to the iPhone 16 cited the delay in Siri features as a reason for their decision [4] - The lowered price target from Morgan Stanley went from $275 to $252, reflecting concerns over the impact of Siri's delays on future iPhone sales [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Photronics, Inc. and its officers or directors [1] Financial Performance - Photronics reported second quarter 2025 revenue of $210.99 million, a 2.8% year-over-year decline, missing consensus estimates by $1.01 million [3] - Non-GAAP earnings per share for the same quarter were $0.40, falling short of consensus estimates by $0.08 [3] - The company provided third quarter revenue guidance of $200 million to $208 million, compared to consensus estimates of $220 million [3] Stock Market Reaction - Following the financial results announcement, Photronics' stock price dropped by $3.12 per share, or 15.55%, closing at $16.94 per share on May 28, 2025 [4] Management Changes - Dr. Frank Lee resigned from his position as Chief Executive Officer of Photronics, effective immediately [3]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Luminar Technologies, Inc. and its officers or directors [1] Group 1: Company Developments - On May 14, 2025, Luminar announced the resignation of founder Austin Russell as President and CEO, as well as Chairperson of the Board, following an inquiry by the Audit Committee regarding the Code of Business Conduct and Ethics [3] - Following the announcement of Russell's resignation, Luminar's stock price dropped by $0.80 per share, representing a decline of 16.81%, closing at $3.96 per share on May 15, 2025 [3] Group 2: Legal Context - Pomerantz LLP is recognized as a leading firm in corporate, securities, and antitrust class litigation, with a history of advocating for victims of securities fraud and corporate misconduct [4]

Core Viewpoint - Pomerantz LLP is investigating potential securities fraud or unlawful business practices involving Schrödinger, Inc. and its officers or directors [1] Group 1: Company Developments - On May 20, 2025, Schrödinger announced the departure of its Chief Financial Officer, Geoffrey Porges, which led to a significant decline in the company's stock price by $2.03 per share, or 8.62%, closing at $21.53 per share [3] Group 2: Legal Investigation - Pomerantz LLP, a prominent firm in corporate and securities class litigation, is representing investors in the investigation concerning Schrödinger [1][4]

NEW YORK, June 02, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Meta Platforms, Inc. (“Meta” or the “Company”) (NASDAQ: META).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Meta and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the class action] On May 15, 2025, ...